Effect of hydroxyethyl starch infusion on colloid oncotic pressure in hypoproteinemic horses.
OBJECTIVE
To determine the effect of hydroxyethyl starch (HES) on colloid oncotic pressure (pi) during fluid resuscitation of hypoproteinemic horses and to evaluate the clinical usefulness of direct and indirect methods for determination of pi before and after infusion of a synthetic colloid.


METHODS
Prospective clinical study.


METHODS
11 hypoproteinemic horses.


METHODS
Horses received IV infusions of 8 to 10 ml of a 6% solution of HES/kg (3.6 to 4.5 ml/lb) of body weight during fluid resuscitation. Blood samples were obtained for determination of plasma measured colloid oncotic pressure (pi meas) and plasma total protein and albumin (A) concentrations. Plasma globulin concentration (G) was calculated as the difference between plasma total protein and albumin concentrations. Calculated values for colloid oncotic pressure (piA + G) were determined by use of a predictive nomogram previously developed for horses.


RESULTS
There was no significant difference between the means of pi meas and piA + G at the beginning of HES infusion. After HES infusion, the mean of pi meas was increased significantly from baseline for 6 hours. Mean plasma total protein and albumin concentrations and piA + G were decreased significantly from baseline for 24 hours. Differences between mean pi meas and piA + G after HES infusion were significant for 24 hours.


CONCLUSIONS
There was good agreement between plasma pi meas and piA + G in blood samples obtained from hypoproteinemic horses immediately before infusion of HES. Use of a predictive nomogram did not, however, account for the oncotic effect of HES. Results of comparison of pi meas to piA + G after HES infusion suggest that a significant oncotic effect was maintained for 24 hours in the study horses.
Jones
P A
PA
Department of Clinical Studies, School of Veterinary Medicine, New Bolton Center, University of Pennsylvania, Kennett Square, PA 19348, USA.
Bain
F T
FT
Byars
T D
TD
David
J B
JB
Boston
R C
RC
D000818:Animals; D001798:Blood Proteins / Q000032:analysis; D003102:Colloids; D005440:Fluid Therapy / Q000662:veterinary*; D006734:Horse Diseases / Q000503:physiopathology / Q000628:therapy*; D006736:Horses; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007019:Hypoproteinemia / Q000503:physiopathology / Q000628:therapy / Q000662:veterinary*; D007262:Infusions, Intravenous / Q000662:veterinary; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011312:Pressure; D011446:Prospective Studies; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome
D001798:Blood Proteins; D003102:Colloids; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D012709:Serum Albumin